Core Alternative Capital’s Moderna MRNA Stock Holding History

Core Alternative Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5	Closed	-$142	–	348
2025 Q1	$142	Hold	5	–	–	﹤0.01%	334
2024 Q4	$208	Hold	5	–	–	﹤0.01%	347
2024 Q3	$334	Hold	5	–	–	﹤0.01%	344
2024 Q2	$594	Hold	5	–	–	﹤0.01%	332
2024 Q1	$533	Sell	5 -120	-96%	-$12.1K	﹤0.01%	327
2023 Q4	$12.4K	Sell	125 -14	-10%	-$1.18K	﹤0.01%	284
2023 Q3	$14.4K	Hold	139	–	–	﹤0.01%	284
2023 Q2	$16.9K	Buy	139 +7	+5%	+$934	﹤0.01%	248
2023 Q1	$20.3K	Buy	132 +14	+12%	+$2.31K	﹤0.01%	225
2022 Q4	$21.2K	Sell	118 -1	-0.8%	-$164	﹤0.01%	214
2022 Q3	$14K	Buy	119 +12	+11%	+$1.82K	﹤0.01%	250
2022 Q2	$15K	Buy	107 +12	+13%	+$1.72K	﹤0.01%	242
2022 Q1	$16K	Buy	95 +81	+579%	+$13.6K	﹤0.01%	229
2021 Q4	$4K	Buy	+14	New	+$4.09K	﹤0.01%	214

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Core Alternative Capital's MRNA Position: Q2 2025 in Review

Core Alternative Capital sold out of Moderna (MRNA) in Q2 2025, closing a stake of 5 shares — an estimated $142 sold.

Core Alternative Capital first reported a position in MRNA in Q4 2021 and held it in 14 quarters. The position peaked at $21.2K in Q4 2022. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

Core Alternative Capital reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
Core Alternative Capital sold 5 Moderna shares in Q2 2025, an estimated $142.
Core Alternative Capital first reported a position in Moderna in Q4 2021 and held it in 14 quarters.
Core Alternative Capital's Moderna position peaked at $21.2K in Q4 2022.
674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on Core Alternative Capital's 13F filing for Q2 2025, filed 5 Aug 2025.